Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vincent Young

Ophthalmology Philadelphia, PA Medical Doctor

NPI 1841255882 CMS profile 356450

5401 Old York Rd, Klein 205, Philadelphia, PA 19141

Open in the dashboard

General payments

$3,830

131 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vincent Young of Philadelphia, PA is reported in the CMS Open Payments database as having received $3,830 across 131 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $766 22
2024 General $663 19
2023 General $385 17
2022 General $571 16
2021 General $378 17
2020 General $439 21
2019 General $629 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vincent Young
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Vincent Young were reported at $766. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Vincent Young Ophthalmology median Middle half National median
2019 $629 $258 $104–$655 $163
2020 $439 $126 $45–$321 $114
2021 $378 $205 $76–$534 $132
2022 $571 $266 $100–$678 $149
2023 $385 $308 $117–$745 $160
2024 $663 $340 $127–$846 $164
2025 $766 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $558 21 payments
  2. Oyster Point Pharma, Inc. $500 15 payments
  3. Alcon Vision LLC $400 13 payments
  4. Bausch & Lomb, a division of Bausch Health US, LLC $359 14 payments
  5. AbbVie, Inc. $318 9 payments
  6. Johnson & Johnson Surgical Vision, Inc. $315 4 payments
  7. Novartis Pharmaceuticals Corporation $249 7 payments
  8. Bausch & Lomb Americas Inc. $235 10 payments
  9. Sun Pharmaceutical Industries Inc. $200 9 payments
  10. Aerie Pharmaceuticals, Inc. $169 10 payments
  11. Other $528 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,669 126 payments
  2. Gift $82 3 payments
  3. Education $80 2 payments
Products named General payments · program years 2019–2025
  1. TYRVAYA $398 11 payments
  2. VYZULTA $291 14 payments
  3. Cequa $200 9 payments
  4. LUMIGAN $198 8 payments
  5. DURYSTA $177 6 payments
  6. Rocklatan $172 7 payments
  7. VERITAS Vision System $164 2 payments
  8. VUITY $161 3 payments
  9. Healon Duet Pro $151 2 payments
  10. DUREZOL $144 2 payments
  11. Other $2,413 93 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

3,115

Median for Ophthalmology: 891

Drug cost

$268,799

Median for Ophthalmology: $68,233

Branded share of claims

14.7%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 83 $62,573
Lumigan Bimatoprost Brand 111 $41,186
Prednisolone Acetate Generic 699 $37,282
Cyclosporine Generic 48 $21,321
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 83 $16,531
Travoprost Generic 112 $13,624
Simbrinza Brinzolamide/Brimonidine Tart Brand 60 $13,386
Miebo Perfluorohexyloctane/Pf Brand 13 $10,359
Combigan Brimonidine Tartrate/Timolol Brand 23 $8,391
Vyzulta Latanoprostene Bunod Brand 13 $7,624

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$66,304

Medicare's payments for the services billed

Medicare patients

275

Average age 73

Services billed

528

179 women, 96 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 48%
Arthritis 48%
Chronic kidney disease 37%
Ischemic heart disease 24%
Heart failure 19%
Cancer 17%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TYRVAYA
  • Oyster Point Pharma, Inc. $102
$102 — —
LUMIGAN
  • AbbVie, Inc. $71
$71 111 —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $61
$61 — —
Rocklatan
  • Alcon Vision LLC $43
$43 12 —
DURYSTA
  • AbbVie, Inc. $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

131 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record